Charles River Laboratories Intl. Inc vs United States Oil ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $286.58 (market cap $13.46B), while United States Oil ETF trades at $127.13. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| CRL | USO | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | — |
52-Week High | $282.00 | $152.96 |
52-Week Low | $145.57 | $66.17 |
Enterprise Value | $16.30B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
USO trades at $127.36, up 1.14% with bullish technical signals from moving averages. The stock faces mixed sentiment as oil markets balance supply disruptions from Middle East tensions against OPEC's downward demand revisions. Technical indicators show strong momentum with ADX signaling trend strength while RSI remains neutral, suggesting room for further movement.
The outlook remains volatile with geopolitical risks driving price action. Upside potential exists if Middle East supply constraints persist, but demand destruction concerns and inventory builds present headwinds. Investors should monitor Strait of Hormuz developments and EIA inventory data for directional catalysts.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →